

# Saw Palmetto Max-V

## Male Health

### DESCRIPTION

Saw Palmetto Max-V capsules, supplied by Douglas Laboratories®, provides 160 mg of standardized saw palmetto in each vegetarian capsule.

### FUNCTIONS

As men age, the function of their prostate gland tends to change. This change during the normal aging process can cause alterations in the functioning of urinary health, including hesitancy, urgency, and increased frequency of urination.

Studies indicate that saw palmetto may be able to inhibit the conversion of testosterone to its more active and potentially deleterious form, dihydrotestosterone (DHT), via inhibition of alpha-5-reductase. Saw palmetto not only inhibits the binding of DHT to cellular receptors, but also has alpha1-adrenoceptor-inhibitory properties.

Alpha1-adrenoceptor antagonism may be responsible for saw palmetto's ability to provide support to the urinary tract and prostate. Saw palmetto extracts have also been found to inhibit the biosynthesis of proinflammatory prostaglandins and leukotrienes.

### INDICATIONS

Saw Palmetto Max-V may be a useful dietary supplement for those men who wish to help maintain healthy prostate function.

### FORMULA (#77367)

#### Each Vegetarian Capsule Contains:

Saw Palmetto ..... 160 mg  
(berry, standardized to 30% fatty acids)

In a 100 mg. base of non-standardized Saw Palmetto.

### SUGGESTED USE

Adults take 1 capsule twice daily between meals or as directed by physician.

### SIDE EFFECTS

No adverse side effects reported.

### STORAGE

Store in a cool, dry place, away from direct light. Keep out of reach of children.

### REFERENCES

Briley, M., Carilla, E., Roger, A. et al. A new treatment of prostatic hyperplasia. Permixon® has antiandrogen effects at two complementary levels. *New Trends Androlog Sci* (1985);1:24-26.

Carilla, E., Roger A., Briley, M. et al. The lipido-sterolic extract of *Serenoa repens* B: new treatment of prostatic hyperplasia, with antiandrogen effects at two complementary levels. *Exerpta Medica* (1986);216-223.

Carraro, J. C., Raynaud, J.P., Koch, G. et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. *Prostate* (1996);29:231-40.

Champault, G., Patel, J. C., Bonard, A. M. A double-blind trial of an extract of the plant *Serenoa repens* in benign prostatic hyperplasia. *Br J Clin Pharmacol* (1984);18:461-462.

Plosker, G. L., Brogden, R. N. *Serenoa repens* (Permixon®) a review of its pharmacology and therapeutic efficacy in Benign prostatic hyperplasia. *Drugs Aging* (1996);9:379-395.

**These statements have not been evaluated by the Food and Drug Administration.  
This product is not intended to diagnose, treat, cure, or prevent any disease.**

**Manufactured by  
Douglas Laboratories  
600 Boyce Road  
Pittsburgh, PA 15205  
800-245-4440**